ArticleJournal of inflammation research2025
Turmeric and
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Macrophage activation syndrome (MAS) is a spectrum of cytokine storm syndrome (CSS) associated with autoimmune conditions. Due to the high number of cytokine storm patient deaths, mainly those that occurred during the COVID-19 pandemic and the lack of effective treatments against CSS spectrums, many people returned to nature and used plant-based remedies at the household level. Methods: This study investigated the anti-inflammatory activity of commonly used medicinal plant decoctions; Turmeric (Tur) and Results: A restoration in weight gain was noticed on day 8 by 2.8 ± 1.722 and 1.7 ± 1.976 g, for MAS Tur and MAS Euc, respectively. Levels of TNF-α and CCL2 in mice sera showed a peak after 2 hrs of LPS and CPG treatment in the MAS group. However, a significant reduction of 85.9% and 84.3% in TNF-α, and 77.1% and 54.6% in CCL2 were observed for MAS Tur and MAS Euc, respectively. In contrast, the reduction in IL-6 was less in MAS-Tur and MAS-Euc when compared to MAS-Dex (6.0%, 5.2%, and 17.4%, respectively). Cytokine gene expression in lung tissue at day 10 revealed a significant reduction in the expression of IL-1β, TNF-α, IL-6, and TGF-β in the MAS Tur and MAS Euc groups compared to the MAS group. Histopathological investigation revealed that lung tissue in MAS Tur and MAS Euc groups showed mild to moderate inflammatory areas with no signs of necrosis compared to the MAS group. High MMP-9 expression was noticed in the MAS group with a score of positively stained neutrophils of 3.8 ± 1.6 that has been reduced to 1.9 ± 0.9 and 2.3 ± 0.7 in MAS Tur and MAS Euc groups, respectively. Conclusion, natural plant extracts may help ameliorating MAS in a better way than dexamethasone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.